



## **NES Reprocessed 0.9mm Turbo-Elite Laser Atherectomy Catheter**

**REF # R-410-152**

### **INSTRUCTIONS FOR USE**



2142 Thomaston Avenue  
Waterbury, CT 06704  
203-756-2111

[www.smarthealth-care.com](http://www.smarthealth-care.com)



**Manufacturers:**  
**Northeast Scientific, Inc.**  
**2142 Thomaston Avenue**  
**Waterbury, CT 06704 U.S.A.**

## **1. DESCRIPTION:**

The NES Reprocessed Spectranetics Turbo-Elite Laser Catheters are percutaneous intravascular devices constructed of multiple optical fibers arranged around a guidewire lumen. Catheter sizing identification is printed on the catheters.

For NES Reprocessed Spectranetics Turbo-Elite Laser Catheters, Over-The-Wire (OTW) catheters, a Luer adapter located at the proximal end of the usable length facilitates the use of the laser catheter over the appropriately sized guidewire (0.014", 0.018", and 0.035"), see insert below.

### **Mechanism of Action for Turbo-Elite Catheters**

The multifiber laser catheters transmit ultraviolet energy from the Spectranetics CVX-300™ Excimer Laser to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photoablate lesions which may be comprised of atheroma, fibrosis, calcium, and thrombus; thus, recanalizing diseased vessels (photoablation is the process by which energy photons cause molecular bond disruption at the cellular level without thermal damage to surrounding tissue). The Spectranetics laser catheters have a proprietary lubricious coating to ease their trackability through arteries.


### **Glossary of Special Terms**

Retrograde Fashion = In the direction opposite to blood flow

Antegrade Fashion = In the direction of blood flow

Baseline Angiography = Angiographic record of blood vessels

Contralateral Approach = Arterial access by a customer approach



**Fig. 1: NES Reprocessed 0.9mm Turbo-Elite Laser Atherectomy Catheter**

**Table 1.1 Turbo-Elite Laser Atherectomy Catheter OTW Models**

<b>Device Description</b>	0.9mm
<b>Model #</b>	R-410-152
<b>Guidewire Compatibility (in)</b>	0.014
<b>Max. Tip Diameter (in)</b>	0.038
<b>Max. Shaft Diameter (in.)</b>	0.047
<b>Working Length (cm)</b>	150
<b>Sheath Compatibility (Fr.)</b>	4

**2. INDICATIONS FOR USE:**

The NES Reprocessed 0.9mm Turbo-Elite™ Laser Atherectomy Catheter (0.014" guidewire compatible and over-the-wire configuration) is indicated for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusions.

The 0.014" Over-the-wire (OTW) Turbo-Elite laser catheters are also indicated for use as an accessory to the use of the Turbo-Tandem System in the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents, when used in conjunction with Percutaneous Transluminal Angioplasty (PTA).

**3. CONTRAINDICATIONS:**

No known contraindications.

**4. WARNINGS:**

**Federal (USA) law restricts this device to sale by or on the order of a physician with appropriate training.**

NES Reprocessed Spectranetics' Turbo-Elite Laser Catheters CVX-300™ Excimer Laser software requirements:

<b>Software</b>	<b>Catheter Maximum Rep Rate</b>
V3.8XX	80 Hz
V3.7XX	40 Hz

When the laser catheter is in the body, it should be manipulated only while it is under fluoroscopic observation with radiographic equipment that provides high quality images.

This device is designated for use solely as a component of the Spectranetics CVX-300™ Excimer Laser System.

Adequate instructions for the safe installation of the Spectranetics CVX-300™ Excimer Laser System are provided in servicing information provided by Spectranetics and should be followed.

For treatment of ISR, the 0.014" OTW Turbo-Elite laser catheters should be used. Prior to atherectomy with any NES Reprocessed Turbo Elite laser catheter, flush all residual contrast media from the introducer sheath or guide catheter and in-line connectors. Saline must be infused throughout the entire atherectomy procedure.

For the treatment of In-stent Restenosis (ISR), clinical data is not available on the following patient population and alternative therapies should be considered for patients exhibiting the following angiographic criteria:

1. Ipsilateral and/or contralateral iliac (or common femoral) artery stenosis  $\geq 50\%$  diameter stenosis that is not successfully treated prior to index procedure (e.g. where a perforation occurred requiring a covered stent) or with final residual stenosis  $\geq 30\%$  documented by angiography.
2. Identification of any native vessel lesion (excludes in-stent restenosis) proximal to the target stent in the femoropopliteal segment  $> 50\%$  that is not successfully treated prior to index procedure (e.g. complication requiring additional treatment) or with final residual stenosis  $\geq 30\%$  documented by angiography. The lesion length must be treatable with a single stent (if required). The lesion must not be contiguous with the target lesion; at least 2 cm of normal appearing vessel between the lesion and target lesion/ target stent or between deployed stent (if required) and the target lesion/ target.
3. Planned or predicted cardiovascular surgical or interventional procedures prior to completion of the 30-day follow-up (including, but not limited to aortic, renal, cardiac, carotid, contralateral femoropopliteal, and contralateral below the knee).
4. Identification of any lesion distal to the stent  $> 50\%$  that will require preplanned or predicted treatment during the index procedure or within 30 days of the index procedure.
5. Grade 4 or 5 stent or proximal to the target stent, or where evidence of stent protrusion into the lumen is noted on angiography in two orthogonal views. Stent integrity may be characterized according to the following scale:

Grade	Description
0	No strut fracture
I	Single tine fracture
II	Multiple tine fracture
III	Stent fracture(s) with preserved alignment of the components
IV	Stent fracture(s) with mal-alignment of the components
V	Stent fracture(s) in a trans-axial spiral configuration

## 5. PRECAUTIONS:

This catheter has been sterilized using Ethylene Oxide and is supplied STERILE. The device is designated and intended for SINGLE USE ONLY and must not be re-sterilized and/or reused. DO NOT re-sterilize or reuse this device, as these actions can compromise device performance or increase the risk of cross-contamination due to inappropriate reprocessing. Reuse of this single use device could lead to serious patient injury or death and voids manufacturer warranties.

Reuse of this single use device could result in, but is not limited , to the following: serious patient injury, device malfunctions or death. Handling of reprocessed devices may vary during use.

Store in a cool, dry place. Protect from direct sunlight and high temperatures (greater than 60°C or 140°F). The sterility of the product is guaranteed only if the package is unopened and undamaged. Prior to use, visually inspect the sterile package to ensure that the seals have not been broken.

Do not use the catheter if the integrity of the package has been compromised. Do not use catheter product if its "Use Before Date," found package labeling, has passed.

Before use, examine carefully all of the equipment to be used in the procedure for defects. Do not use any equipment if it is damaged.

After use, dispose of all equipment in accordance with applicable specific requirements relating to hospital waste, and potentially biohazardous materials.

Read the Operator's Manual thoroughly before operating the CVX-300™ Excimer Laser. Pay particular attention to the Warnings and Responsibility section of the manual which explains Notes, Cautions, and Warnings to be followed to ensure safe operation of the system.

During the procedure, appropriate anticoagulant and vasodilator therapy should be provided to the patient per the institution's protocol.

Saline must be infused throughout the entire lasing process.

## **6. POTENTIALADVERSE EFFECTS**

Use of the NES Reprocessed Turbo-Elite in conjunction with the CVX-300™ Excimer Laser may contribute to the following complications: spasms, major dissection, thrombus, distal embolization, perforation, death, reintervention, ALI, major amputation, bypass surgery, hematoma with surgery, re-occlusion, pseudoaneurysm, renal failure, bleeding, nerve injury, AV fistula formation, endarterectomy, infection, stroke, myocardial infarction, arrhythmia or other.

## **7. Individualization of Treatment:**

The risks and benefits of the NES Reprocessed Turbo Elite should be carefully considered for each patient before use of the device.

Use of the Turbo Elite device may be considered after initial conventional crossing attempts with guidewires are unsuccessful due to:

- A rounded or eccentric occlusion stump deflecting the guidewire to a subintimal passage.
- The guidewire repeatedly being deflected into a large collateral branch flush with the occlusion stump.
- Calcification obstructing completion of the guidewire passage within the obstructed lumen.

Additionally, recanalization of native arteries may be considered in patients presenting with occluded bypass grafts.

Patient selection and clinical techniques should be conducted according to instructions provided in Section 2, "Indications for Use," and Section 8, "Operator's Manual."

## **8. OPERATOR'S MANUAL:**

The device described in this document can be operated within the following energy ranges on the CVX-300™ Excimer Laser:

**Table 6.1 Energy Parameters**

Device Description	0.9mm
--------------------	-------

<b>Model No.</b>	R-410-152
<b>Fluence</b>	30-80
<b>Repetition Rate</b>	25-80*
<b>Laser On/Off Time</b>	Continuous On*

Recommended calibration settings: 45 Fluence, 25 Hz

\*80 Hz maximum repetition rate is for software V3.8XX. For software V3.7XX, the maximum repetition rate is 40 Hz.

## **9. HOW SUPPLIED:**

### **9.1. Sterilization**

For single use only. Do not re-sterilize and/or reuse.

The Spectranetics laser catheters are supplied sterile. Sterility is guaranteed only if the package is unopened and undamaged.

### **9.2. Inspection Prior to Use**

Before use, visually inspect the sterile package to ensure that seals have not been broken. All equipment to be used for the procedure, including the catheter, should be examined carefully for defects. Examine the laser catheter for bends, kinks or other damage. Do not use if it is damaged.

## **10.COMPATIBILITY:**

- The Spectranetics Laser Atherectomy Catheter is designed and intended to be used exclusively with the Spectranetics CVX-300™ Excimer Laser.
- Do not use in combination with any other laser system.
- Guidewire Compatibility
- See Catheter Specification Table in Section 1.

## **11.DIRECTIONS FOR USE:**

### **Procedure Set-Up**

Some or all of the following additional materials, which are not included in the laser catheter package, may be required for the procedure (these are single use items only-do not re-sterilize or reuse):

- Introducer sheaths and/or femoral guiding catheter(s) in the appropriate size and configuration to select the peripheral artery and facilitate largest laser catheter to be used.
- Tuohy-Borst "y" adapter or hemostatic valve(s).
- Sterile normal saline.
- Standard contrast media.
- 0.014" guidewires.

The use of the CVX-300™ Excimer Laser is restricted to physicians who are trained in peripheral vascular intervention and who meet the training requirements listed below. These requirements include, but are not limited to:

1. Training of laser safety and physics.
2. Review of patient films of lesions that meet the indications for use.
3. A review of cases demonstrating the Excimer Laser Ablation technique in occlusions that meet the indications for use.
4. A review of laser operation followed by a demonstration of the CVX-300™ Excimer Laser.
5. Hands on training with the CVX-300™ Excimer Laser and appropriate model.

Using sterile technique, open the sterile package. Remove the packaging wedges from the tray and gently lift the laser catheter from the tray while supporting the black laser connector, also known as the proximal end, proximal coupler, or proximal connector. Please note that the proximal end of the laser catheter connects only to the CVX-300™ Excimer Laser, and is not meant to have any patient contact.


Connect the proximal end of the laser catheter to the CVX-300™ Excimer Laser and position the laser catheter in the laser system extension pole. Calibrate the laser catheter following the instructions provided in the CVX-300™ Excimer Laser Operator's Manual

- 1) Use standard femoral puncture technique to insert a 4 Fr. introducer sheath into the common femoral artery in antegrade or retrograde fashion for contralateral approaches. Heparinize intravenously using the protocol for heparinization.
- 2) Perform baseline angiography by injecting contrast medium through the introducer sheath or guiding catheter. Obtain images in multiple projections, delineating anatomical variations and morphology of the lesion(s) to be treated.
- 3) Introduce a 0.014" guidewire to the peripheral occlusion via the introducer sheath or guiding catheter.
- 4) Size and choose the laser catheter appropriately:

**Table 12.1 Recommended Sizing**

Catheter Size	Proximal Vessel Diameter
0.9mm	≥ 1.4mm

- 5) Hydrate the outer jacket of the catheter to activate the hydrophilic coating. Either dip the catheter in a basin or wipe with wet gauze using an appropriate sterile solution.
- 6) Flush the guidewire lumen of the laser catheter using 5-10 ml of heparinized saline.
- 7) Introduce the distal tip of the NES Reprocessed laser catheter over the selected guidewire. Under fluoroscopic control, guide the laser catheter to the lesion. The laser catheter's radiopaque band marker indicates its position relative to the lesion.



**Fig. 2 (not to scale)**

**Note: Always monitor laser catheter movement and the radiopaque tip marker position with fluoroscopy. The movement and rate of advancement of the catheter distal tip should correspond directly with the rate of advancement being applied to the proximal shaft of the catheter.**

**If corresponding movement is not apparent, reassess the lesion morphology, the laser energy being applied and the status of support equipment prior to continued treatment.**

**In the absence of apparent catheter movement, care should be taken not to deliver excessive laser energy.**

- 8) Inject contrast medium solution through the introducer sheath or guiding catheter to verify the positioning of the laser catheter under fluoroscopy.
- 9) Following confirmation that the laser catheter's position is in contact with the target lesion, and using normal saline solution:
  - a) Flush all residual contrast media from the introducer sheath or guide catheter and in-line connectors.
  - b) Flush all residual contrast media from the lasing site and vascular structures adjacent to the lasing site, prior to activating the CVX-300™ Excimer Laser. Warning: Do not activate the laser in the presence of contrast.
  - c) Please refer to the Saline Infusion Protocol section of the Instructions for Use and perform saline flush and infusion per the instructions.
- 10) When using Turbo-Elite Laser Atherectomy Catheter models, the CVX-300™ Excimer Laser will continuously deliver energy as long as the footswitch is depressed. The length of the laser train is controlled by the operator. It is generally recommended not to exceed 20 seconds of continuous lasing.
- 11) **Step-by-Step Method for Total Occlusion**
  - a) Depress the footswitch, activating the CVX-300™ Excimer Laser, and slowly, less than 1 mm per second, advance the laser catheter 2-3 mm into the total occlusion, allowing the laser energy to remove the desired material. Release the footswitch to deactivate the CVX-300™ Excimer Laser.
  - b) Advance the guidewire beyond the distal tip of the laser catheter further into the occlusion, a few millimeters, and reactivate the laser as described in Step a above.
  - c) Continue in this step-by-step manner where the guidewire and then the laser catheter are advanced and activated (mm by mm) until the catheter reaches the last 3-5 mm of the occlusion.
  - d) Cross the last 3-5 mm of the occlusion and enter the patent distal vessel with the guidewire first, followed by the activated laser catheter over-the-wire.
  - e) Leaving the guidewire in position, pull back the laser catheter and inject contrast medium through the guiding catheter and examine the lesion via fluoroscopy.
  - f) Additional laser passes may be performed over-the-wire to achieve greater debulking of the lesion.
  - g) If resistance to catheter advancement is met (such as calcium), immediately stop lasing by releasing the footswitch to deactivate the CVX-300™ Excimer Laser. The fluence and repetition rates can be increased in order to advance. To avoid the potential of heat build-up, the catheter must be advanced while lasing.
- 12) **Standard Method for Treating Stenoses**
  - a) Depress the footswitch, activating the CVX-300™ Excimer Laser, and slowly, less than 1 mm per second, advance the laser catheter through the stenosis. Release the footswitch to deactivate the CVX-300™ Excimer Laser.
  - b) Additional laser passes may be performed over-the-wire to achieve greater debulking of the lesion. If resistance to catheter advancement is met (such as calcium), immediately stop lasing by releasing the footswitch to deactivate the CVX-300™ Excimer Laser. The fluence and repetition rates can be increased in order to advance. To avoid the potential of heat build-up, the catheter must be advanced while lasing.

- 13) There is no need to remove the laser catheter from the patient in order to increase or decrease either the fluence or pulse repetition rate; as the laser catheter was previously calibrated. Refer to the CVX-300™ Excimer Laser Operator's Manual.
- 14) Following laser recanalization, perform follow-up angiography and balloon angioplasty if needed. Stenting may be performed as required, in instances of acute recoil, major perforation, etc.
- 15) Perform saline infusion protocol as required.

**Note: Use of two operators is recommended for this technique. It is recommended that the primary physician-operator advance the laser catheter and operate the laser system foot pedal. A scrub assistant should manage the saline infusion control syringe and (if appropriate) depress the fluoroscopy pedal.**

- a) Before the laser procedure, obtain a 500 ml bag of 0.9% normal saline (NaCl). It is not necessary to add heparin or potassium to the saline solution. Connect the bag of saline to a sterile intravenous line and terminate the line at a port on a triple manifold.
- b) If applicable, cannulate the ostium of the artery with an appropriate "large lumen" guide catheter in the usual fashion. It is recommended that the guide catheter not have side holes.
- c) Under fluoroscopic guidance, advance the laser catheter into contact with the lesion. If necessary, inject contrast to help position the tip of the laser catheter. If contrast appears to have become entrapped between the laser catheter tip and the lesion, the laser catheter may be retracted slightly (1-2 mm) to allow antegrade flow and contrast removal while flushing the system with saline. However, before lasing, ensure that the laser catheter tip is in contact with the lesion.
- d) Expel any residual contrast from the control syringe back into the contrast bottle. Clear the triple manifold of contrast by drawing up saline through the manifold into the control syringe.
- e) Remove the original control syringe from the manifold and replace it with a fresh 20 ml luer-lock control syringe. This new 20 ml control syringe should be primed with saline prior to connection to reduce the chance for introducing air bubbles. (Merit Medical and other vendors manufacture 20 ml control syringes.)
- f) Flush all traces of blood and contrast from the manifold, connector tubing, y-connector, and introducer sheath or guide catheter, with at least 20-30 ml of saline (several syringes of saline). When this initial flushing is completed, refill the 20 ml control syringe with saline.
- g) Under fluoroscopy, confirm that the tip of the laser catheter is in contact with the lesion (advance the laser catheter if necessary), but do not inject contrast.
- h) When the primary operator indicates that he/she is ready to activate the laser system, the scrub assistant should turn the manifold stopcock off to pressure and inject 10 ml of saline as rapidly as possible (within 1-2 seconds). This bolus injection is to displace and/or dilute blood down to the level of the capillaries and limit back-bleeding of blood into the laser ablation field.
- i) After the injection of the initial 10 ml bolus and without stopping the motion of injection, the scrub assistant should next slow down the rate of injection to minimum of 2-3 ml second through a combination of the guidewire lumen and/or sheath. This portion of the saline infusion is to displace and/or dilute the antegrade blood flow entering the laser ablation field. At the instant the scrub assistant slows down the injection rate, the primary operator should activate the CVX-300™ Excimer Laser by depressing the foot pedal and begin a lasing sequence.

- j) The length of the laser train is controlled by the operator. It is generally recommended not to exceed 20 seconds of continuous lasing. Saline must be infused throughout the entire lasing process.
- k) Terminate the saline injection at the end of the lasing train. Turn the manifold stopcock back to pressure and refill the control syringe with 20 ccs of saline in preparation for the next lasing sequence.
- l) Each subsequent laser train should be preceded by a bolus of saline and performed with continuous saline infusion as described in steps h-k.
- m) If contrast is used to assess treatment results during the course of a laser treatment, repeat steps d-g prior to reactivation of the CVX-300™ Excimer Laser (before activating the laser repeat steps h-k).

**Note: Depending on which approach is used, antegrade or contralateral, saline can be administered through the sheath (antegrade approach) or laser catheter inner lumen (contralateral approach). When the contralateral approach is used, smaller diameter guidewires are suggested to allow adequate saline infusion at the treatment site.**

Turbo Elite is a registered trademark of Spectranetics Corporation and/or Philips AG.